Produktinformation
- Vercyte, A-8103, Amedel
- 1,1′-(1,4-Piperazinediyl)bis[3-bromo-1-propanone]
- 1,1′-(Piperazine-1,4-diyl)bis(3-bromopropan-1-one)
- 1,4-Bis(3-bromopropionyl)piperazine
- 1,4-Di(3-bromopropionyl)piperazine
- 1-Propanone, 1,1'-(1,4-piperazinediyl)bis[3-bromo-
- 3-Bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one
- A 1803
- Amedel
- N,N'-Bis(3-bromopropionyl)piperazine
- Mehr Synonyme anzeigen
- Nsc-25154
- Piperazine, 1,4-bis(3-bromopropionyl)-
- Vercyte
Pipobroman (Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. Pipobroman has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). Pipobroman allows, within 3 months, to attain a response in more than 90% of patients, without clinically relevant toxicities. The 10-years risk of thrombosis of patients treated with Pipobroman is about 15%, The anti-proliferative activity of Pipobroman on bone marrow megakaryocytes seems of particular value in lowering the occurrence of post-PV and post-ET MMM, whose risk is the lowest registered with available treatments. The 10-year risk of acute leukemia with Pipobroman is 5% in PVand 3% in ET, which is only slightly higher than that expected as a natural evolution of the disease. In conclusion, the use of Pipobroman is a definite alternative to hydroxyurea in patients with PV and ET at high risk of thrombosis.
Chemische Eigenschaften
Technische Anfrage zu: TM-T4570 Pipobroman
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.